The NPWT market is currently being driven by factors, such as the rising prevalence of chronic wounds and growing diabetic population. This leads to a higher number of diabetic foot ulcers and increase in the geriatric population across the world. Few factors are hindering the market growth, which includes the high cost of the NPWT therapy, and complications associated with NPWT devices. The market is witnessing continuous advancements in the products and technologies used. Companies, such as 3M (Acelity LP Inc.), Smith & Nephew, and ConvaTec Group PLC, hold large market shares, in the NPWT devices. Single-use NPWT products are gaining popularity over traditional products in the area of wound care treatment. For example, key players, like Smith & Nephew, have launched a single-use NPWT, PICO, which has gained tremendous popularity, worldwide. Fur ther, ConvaTec Inc. launched the Avelle™ Negative Pressure Wound Therapy (“NPWT”) system. It is the first and only device of this technology, combining negative pressure with the advantages of Hydrofiber® technology. Thus, advancements in technology in negative pressure wound therapy products may drive the market growth, during the forecast period.

The stretch marks treatment market is largely driven by the rising burden of obesity can result in an exponential rise in stretch marks. Lifestyle-related disorders are found having a great influence on the body. Avoiding alcohol, drugs, exercising, and following a healthy diet aid in staying healthy. For instance, as per the WHO it was stated that most of the world's population live in countries where overweight and obesity kill more people than underweight. These factors indicate that there is a high burden of obesity in the world, which is augmenting the number of people having stretch marks. Moreover, there are approximately 44% of unplanned pregnancy cases in Europe and 38% in Asia, which may lead to high growth of the stretch marks treatment market, due to the rising number of pregnancy cases. Because the stretch marks are associated with gestational change that affects between 50% to 90% of women, depending on the race and age of the population. Many women develop stretch marks during their first pregnancy.

The burden of chronic diseases is increasing worldwide. Factors, such as aging population and behavioral changes in lifestyles, are leading to long-term health problems, and their treatment can be expensive. Most deaths by chronic diseases can be attributed to cardiovascular diseases, cancer, and neurological disorders. This rise in the burden of such diseases is contributing to the growth of the prefilled syringesmarket. The market for prefilled syringes is believed to grow, owing to factors, such as increasing adoption of self-care devices, and benefits associated with prefilled syringes. The prefilled syringes make injections easy, accurate, and safe for both patients as well as doctors. Pre-filled syringes have emerged as one of the fastest-growing choices for unit dose medication, as the pharmaceutical industry seeks new and more convenient drug delivery methods that improve safety and efficiency while reducing costs. The increasing applications for the treatment of chronic diseases are leading to the increased demand for prefilled syringe in the market. Prefilled syringes have been used to deliver drug categories, such as vaccines, therapeutic proteins, blood stimulants, and more. The rising preference of these syringes, along with the increasing disease complications, has led major players to increase their R&D expenditure, which is fur ther acting as major driver for the market growth.

整体来看，自上半年 Q1 带来的短暂冲击结束后，医药板块各行业优质公司均 有不俗的增长表现，根据我们草根数据看，医药消费板块全面凸显刚需特性。

三联苗因注册证到期无批签发；四联苗 20H1 批签发 312 万支，同比增长 245%，去年同期因行业事件批签发较少；五联苗 20H1 批签发 358 万支，同比增长 52%，五联苗注册证于 4 月份到期，但由 于库存充足（上周仍批签发 40 万支），预计全年供给不受影响。

2020 年6 月，中检所共批签发疫苗4,961.45 万瓶，同比增长19.21%。2020年1-6 月，累计批签发疫苗29,994.55 万瓶，同比增长22.2%。

新冠疫苗研发始于2020 年 1月，随着候选疫苗进入二期/三期临床，其临床效果、定价政府采购量愈发明朗，我们认为新冠疫苗的利润贡献路径日益清晰，有望从主题驱动转换为基本面驱动。

近年来，随着人血白蛋白临床需求的不断增加，人血白蛋白的进口量不断增大。2014年至今，进口人血白蛋白市场份额基本超过六成以上，除去2019年Q1受部分外资企业GMP到期重新认证影响，其它季度进口人血白蛋白市场份额均多过国产人血白蛋白。

我国居民人均可支配收入每年呈稳定增长的态势，2019年全年人均可支配收入实现3.07万元，增速稳定在8.9%。随着人均可支配收入的稳定增长，我国居民对医疗卫生领域的需求逐步提升，其中对医疗服务的需求增长明显。2018年，我国居民人均医疗服务现金消费支出为808.8元，增速高达20%。我国医院诊疗人次数亦实现稳定增长，达35.77亿次，同比增速稳定在4%。